二甲双胍对1型糖尿病儿童血管功能的影响:一项为期12个月的随机对照试验
这项为期12个月的双盲随机安慰剂对照试验纳入90例8至18岁、BMI高于第50百分位的1型糖尿病儿童,评估二甲双胍对血管功能的影响。结果显示二甲双胍改善血管平滑肌功能(GTN介导的舒张)和糖化血红蛋白,并降低胰岛素剂量,未影响颈动脉/主动脉内中膜厚度、BMI、血脂、血压等,胃肠道副作用更多。作者认为这些获益和良好安全性值得进一步考虑其应用。
要点
- 二甲双胍使GTN介导的舒张改善3.3个百分点(95%CI 0.3, 6.3,P=0.03),不依赖HbA1c。
- 二甲双胍使胰岛素剂量减少0.2 U/kg/d(95%CI 0.1, 0.3,P=0.001)。
- 二甲双胍组胃肠道副作用发生率更高(发生率比1.65,95%CI 1.08, 2.52,P=0.02)。
核心结论
- 二甲双胍改善1型糖尿病儿童的血管平滑肌功能和HbA1c,并降低胰岛素剂量;作者认为这些获益和良好安全性值得进一步考虑其应用。
研究设计与样本
- 为期12个月的双盲、随机、安慰剂对照试验,在三级儿科糖尿病门诊开展。
- 共纳入90名8至18岁、BMI高于第50百分位、患有1型糖尿病的儿童,二甲双胍组和安慰剂组各45名。
- 干预为二甲双胍(最高每日2次、每次1 g)或安慰剂。
主要发现
- 二甲双胍组GTN介导的舒张改善3.3个百分点(95%CI 0.3, 6.3,P=0.03),不依赖HbA1c,效应从3个月起出现。
- 二甲双胍组胰岛素剂量减少0.2 U/kg/d(95%CI 0.1, 0.3,P=0.001)。
- 二甲双胍在3个月时对HbA1c有有益效应(P=0.001),12个月期间两组校正HbA1c差异为1.0%(95%CI 0.4, 1.5;10.9 mmol/mol,95%CI 4.4, 16.4),P=0.001。
- 对颈动脉/主动脉内中膜厚度、BMI、血脂、血压或其他心血管危险因素无影响。
- 电子监测评估的中位(95%CI)依从性为75.5%(65.7, 81.5),组间无差异;二甲双胍组胃肠道副作用报告更多(发生率比1.65,95%CI 1.08, 2.52,P=0.02),低血糖或糖尿病酮症酸中毒无差异。
关键数值与推荐
- 二甲双胍组GTN介导的舒张改善3.3个百分点(95%CI 0.3, 6.3,P=0.03)。
- 二甲双胍组胰岛素剂量减少0.2 U/kg/d(95%CI 0.1, 0.3,P=0.001)。
- 12个月期间两组校正HbA1c差异为1.0%(95%CI 0.4, 1.5;10.9 mmol/mol,95%CI 4.4, 16.4),P=0.001。
- 二甲双胍组胃肠道副作用发生率比为1.65(95%CI 1.08, 2.52,P=0.02)。
临床怎么用
- 作者认为二甲双胍在1型糖尿病儿童中改善血管平滑肌功能和HbA1c并降低胰岛素剂量,这些获益和良好安全性值得进一步考虑其应用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Children with type 1 diabetes have vascular dysfunction preceding atherosclerosis. Early interventions are needed to reduce cardiovascular disease. OBJECTIVE: To evaluate the effect of metformin on vascular function in children with type 1 diabetes. DESIGN: Twelve-month double-blind, randomized, placebo-controlled trial. SETTING: Tertiary pediatric diabetes clinic. PARTICIPANTS: Ninety children (8 to 18 years of age), >50th percentile body mass index (BMI), with type 1 diabetes. INTERVENTION: Metformin (up to 1 g twice a day) or placebo. MAIN OUTCOME MEASURE: Vascular function measured by brachial artery ultrasound [flow-mediated dilatation/glyceryl trinitrate-mediated dilatation (GTN)]. RESULTS: Ninety participants were enrolled [41 boys, 13.6 (2.5) years of age, 45 per group], 10 discontinued intervention, and 1 was lost to follow-up. On metformin, GTN improved, independent of glycosylated hemoglobin (HbA1c), by 3.3 percentage units [95% confidence interval (CI) 0.3, 6.3, P = 0.03] and insulin dose reduced by 0.2 U/kg/d (95% CI 0.1, 0.3, P = 0.001) during 12 months, with effects from 3 months. Metformin had a beneficial effect on HbA1c at 3 months (P = 0.001) and difference in adjusted HbA1c between groups during 12 months was 1.0%; 95% CI 0.4, 1.5 (10.9 mmol/mol; 95% CI 4.4, 16.4), P = 0.001. There were no effects on carotid/aortic intima media thickness, BMI, lipids, blood pressure, or other cardiovascular risk factors. Median (95% CI) adherence, evaluated by electronic monitoring, was 75.5% (65.7, 81.5), without group differences. More gastrointestinal side effects were reported on metformin (incidence rate ratio 1.65, 95% CI 1.08, 2.52, P = 0.02), with no difference in hypoglycemia or diabetic ketoacidosis. CONCLUSIONS: Metformin improved vascular smooth muscle function and HbA1c, and lowered insulin dose in type 1 diabetes children. These benefits and good safety profile warrant further consideration of its use.
引用
- Anderson JJA, Couper JJ, Giles LC, et al. Effect of Metformin on Vascular Function in Children With Type 1 Diabetes: A 12-Month Randomized Controlled Trial. J Clin Endocrinol Metab. 2017. PMID: 29040598. doi:10.1210/jc.2017-00781
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。